DrugPatentWatch Database Preview
« Back to Dashboard
The generic ingredient in HALAVEN is eribulin mesylate. One supplier is listed for this compound. Additional details are available on the eribulin mesylate profile page.
Generic Entry Opportunity Date for 201532
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 201532
|Physiological Effect||Microtubule Inhibition |
Profile for product number 001
|Active Rx/OTC/Discontinued:||RX||Dosage:||SOLUTION;INTRAVENOUS||Strength||1MG/2ML (0.5MG/ML)|
|Approval Date:||Nov 15, 2010||TE:||RLD:||Yes|
|Regulatory Exclusivity Expiration:||Jan 28, 2019|
|Regulatory Exclusivity Use:||TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE RECEIVED A PRIOR ANTHRACYCLINE-CONTAINING REGIMEN.|
|Regulatory Exclusivity Expiration:||Jan 28, 2023|
|Regulatory Exclusivity Use:||TREATMENT OF PATIENTS WITH UNRESECTABLE OR METASTATIC LIPOSARCOMA WHO HAVE RECEIVED A PRIOR ANTHRACYCLNE-CONTAINING REGIMEN|
|Patent:||➤ Try a Free Trial||Patent Expiration:||Jul 20, 2023||Product Flag?||Substance Flag?||Y||Delist Request?|
Complete Access Available with Subscription